Target Approaches
Target Protein Degradation
Proteolysis-targeting chimeras (PROTACs) are revolutionizing the landscape of drug discovery with their unique mechanism of action that leverages the cell’s own degradation machinery. PROTAC approach involves molecules that are designed to bind to both a target protein and an E3 ubiquitin ligase, effectively flagging the target protein for destruction by the ubiquitin-proteasome system. This approach not only inhibits protein function but also removes the protein entirely from the cellular environment, offering a powerful strategy to tackle previously “undruggable” targets such as transcription factors and non-enzymatic proteins. The versatility of PROTACs lies in their ability to degrade a wide range of proteins, transcending the limitations of traditional small-molecule inhibitors and opening new avenues for therapeutic intervention.
Jubilant Biosys services include the development of multi-method PROTAC assays, high-throughput screening, and structure-activity relationship (SAR) support. Custom-tailored screening platform that include below list of assays.
- PROTAC binding to Target protein (ADP-GLO assay, Fluorescent displacement & SPR).
- Binary binding affinities (HTRF, Fluorescence polarization assay & SPR).
- Ternary complex binding affinities (ALPHA LISA).
- Cell based (Target protein degradation by Jess, Traditional Western blot, HiBiT).
Jubilan Biosys can support client projects involving Target Protein Degradation drug discovery at all stages of preclinical development ranging from protein production to preclinical candidate nomination. Medicinal chemistry strategies are driven by structure-based drug design using information provided by our in-house X-ray crystallographers.